Korea BNC Acquires 44,210 Shares of Dongin Biotech for Business Diversification and Management Participation
[Asia Economy Reporter Lee Jung-yoon] Korea BNC announced on the 13th that it will acquire 44,210 shares of Dongin Biotech, a reagent and testing equipment wholesale and retail company, for 12 billion KRW.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Why This Bonus Grade?" Civil Servant Who Assaulted HR Employee... Court Rules Demotion Is Justified
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
After acquiring the shares, Korea BNC's stake in Dongin Biotech will be 63.2%. The purpose of the acquisition is to strengthen existing business capabilities, diversify business, and participate in management through securing management rights. The scheduled date of share acquisition is July 18 of this year.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
